| Literature DB >> 34254927 |
Wang Aitong1, Zhang Leisheng2, Yu Hao3.
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a widespread pandemic globally and seriously threatened public health. Patients with COVID-19 infection, and in particular, those with severe pneumonia-associated acute respiratory distress syndrome (ARDS) manifested rapid disease progression and the resultant high mortality and morbidity. Advances in fundamental and clinical studies have suggested the feasibility of mesenchymal stem/stromal cell (MSC)-based therapy as an inspiring alternative for ARDS administration. However, the systematic characteristics of the MSC-based cytotherapy and underlying mechanism for COVID-19 associated ARDS by bibliometric analyses are still unknowable. Herein, we took advantage of visual analyses to reveal the overview of ARDS-associated updates, core authors and focused issues, as well as to summarize the comprehensive knowledge of the keywords, authors, institutions with the aid of indicated software. Meanwhile, we have provided a brief overview on the molecular mechanisms and discussed the safety and efficacy of MSC-based therapy for ARDS on the basis of clinical trials. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Mesenchymal stem/stromal cells (MSCs); acute respiratory distress syndrome (ARDS); bibliometric analyses; clinical trials; coronavirus disease 2019 (COVID-19); mechanisms
Mesh:
Year: 2022 PMID: 34254927 DOI: 10.2174/1574888X16666210712212421
Source DB: PubMed Journal: Curr Stem Cell Res Ther ISSN: 1574-888X Impact factor: 3.828